Literature DB >> 28363343

Early analysis of laparoscopic common bile duct exploration simulation.

Phillip M Kemp Bohan1, Christopher R Connelly2, Jeff Crawford2, Nathan W Bronson3, Martin A Schreiber2, Chris W Lucius3, John G Hunter2, Laszlo N Kiraly2, Bruce Ham2.   

Abstract

BACKGROUND: We developed a laparoscopic common bile duct exploration (LCBDE) simulation course for resident surgeons (RS) and practicing surgeons (PS). We hypothesized that course completion would provide LCBDE procedural skills and increase procedure utilization.
METHODS: RS and PS were prospectively enrolled. Pre- and post-course ability were assessed with written examinations and LCBDE simulations. PS completed pre-course, post-course, and 1-year follow-up surveys (5-point Likert-type scale).
RESULTS: 17 RS and 8 PS were enrolled. Median written test scores improved (70.0%-80.0%, p < 0.001) and median LCBDE simulation times (seconds) improved (585-314, p = 0.001) among all participants. Comparing RS and PS, median written assessment scores pre-course (70% vs 72.5%, p = 0.953) and post-course (77.5% vs 80.0%, p = 0.198) were not significantly different. Simulation completion times (seconds) improved similarly from pre-course (608.0 vs 521.5, p = 0.885) to post-course (314.0 vs 373.0, p = 0.287) between groups. PS comfort with LCBDE improved (2-4, p = 0.03). All PS reported LCBDE utilization 1 year post-course.
CONCLUSIONS: The LCBDE course is appropriate for RS and PS. PS also reported increased comfort with LCBDE and procedure utilization.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28363343     DOI: 10.1016/j.amjsurg.2017.03.011

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  1 in total

1.  Combined gastroscopic and choledochoscopic transabdominal nasobiliary drainage.

Authors:  Song-Mei Lou; Min Zhang; Zheng-Rong Wu; Gui-Xing Jiang; Hua Shen; Yi Dai; Yue-Long Liang; Li-Ping Cao; Guo-Ping Ding
Journal:  J Zhejiang Univ Sci B       Date:  2019 Nov.       Impact factor: 3.066

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.